- SUB-TYPE OF MDS:Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML), including patients with CD123 positive AML secondary to MDS
- SEVERITY OF MDS: AML
- NAME OF DRUG: UCART targeting CD123 positive leukaemia cells
- SUB-TYPE OF MDS:Patients AML (acute myeloid leukaemia) who fail to enter morphological remission or have persistence of cytogenetic abnormality following intensive combination chemotherapy at day+100 post-transplant
- SEVERITY OF MDS: AML
- NAME OF DRUG: Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) that express
B7.1 (CD80) and IL-2 (AML cell vaccine)
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Written by Janet Hayden – Lead Myeloid Clinical Nurse Specialist – King’s College Hospital MDS specialist nurse Janet Hayden gave two talks at our recent London Patient meeting at King’s College Hospital. The first one was a report about […]
Read full story
- SUB-TYPE OF MDS:Lower Risk MDS patients who require red cell transfusions but have not received Erythropoietin
- SEVERITY OF MDS: IPSS-R Very Low, Low or Intermediate Risk MDS
- NAME OF DRUG: Luspatercept
- SUB-TYPE OF MDS:Lower Risk MDS With Low Red Blood Cell Transfusion Burden
- SEVERITY OF MDS: IPSS-R Very Low, Low or Intermediate Risk MDS with <5% blasts
- NAME OF DRUG: Roxadustat
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Written by Prof Jude Fitzgibbon, Prof Tom Vulliamy and Prof Inderjeet Dokal, Queen Mary University of London When a patient is first diagnosed with myelodysplastic syndrome (MDS), one of the most frequent questions posed is whether the disease […]
Read full story
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? by Niels Jensen What is precision medicine? In precision medicine the basic idea is to develop a treatment for the specific cancer of individual patients based on a genetic understanding of their disease. Precision medicine has also been […]
Read full story
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? The Harmony Alliance is a first-of-its-kind partnership of over 80 private and public organisations aiming at enabling better and faster treatments for patients with blood cancers such as MDS. Patient Organisations have a very active role in Harmony, and […]
Read full story
Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Report from the MDS Education Forum that took place in November 2018. Interviews by Sophie Wintrich Chief Executive of MDS UK Patient Support Group. What are Myeloid Gene Panels and how are they used in MDS? One of […]
Read full story
Professor David Bowen and Leeds Teaching Hospitals are pleased to announce a new service for patients who would like a specialist MDS consultation but who are unable to, or prefer not to travel to Leeds for a conventional clinic appointment. This is a brand new type of NHS service opening for MDS patients, for online […]
Read full story